CDIO

DEFA14A - Cardio Diagnostics Holdings, Inc. (0001870144) (Filer)

The report reflects the current state of rural cardiovascular care in America and offers an exclusive roadmap for rural health organizations navigating ongoing workforce shortages and access challenges.Cardio Diagnostics Holdings, Inc. (NASDAQ:CDIO), an AI-driven precision cardiovascular medicine company, today announced the release of a new edition of the company’s rural health report, "The State of Rural Hospitals and Cardiovascular Care," aimed at helping rural healthcare leaders, policymakers, and community-based organizations improve cardiovascular care quality and outcomes in rural areas.Ongoing Workforce Shortages and Access ChallengesThe rural healthcare workforce shortage is signifi

8-K - Cardio Diagnostics Holdings, Inc. (0001870144) (Filer)

The new in-house laboratory facility will give Cardio Diagnostics end-to-end ownership of test processing and expand research capabilities for ongoing and future studies in precision monitoring of cardiovascular health. Cardio Diagnostics Holdings, Inc. (NASDAQ:CDIO), an AI-driven precision cardiovascular medicine company, today announced the official launch of its in-house, high complexity CLIA-certified laboratory in Iowa City, Iowa. The new facility gives Cardio Diagnostics end-to-end control over the processing of its multi-omics clinical tests, Epi+Gen CHD™ and PrecisionCHD™, from sample receipt to result delivery, replacing the third-party arrangement previously used for clinical sa

10-Q - Cardio Diagnostics Holdings, Inc. (0001870144) (Filer)

DEFA14A - Cardio Diagnostics Holdings, Inc. (0001870144) (Filer)

DEF 14A - Cardio Diagnostics Holdings, Inc. (0001870144) (Filer)

Cardio Diagnostics Holdings, Inc. (NASDAQ:CDIO) ("Cardio Diagnostics" or the "Company"), a precision cardiovascular medicine company leveraging epigenetics, genetics, and artificial intelligence for the prevention and detection of cardiovascular disease, today announced that it will host an investor conference call on Thursday, August 20, 2026, at 3 p.m. Central Time. The call will provide an overview of the Company’s precision molecular approach to cardiovascular disease prevention and early detection, including updates on its commercially available tests, Epi+Gen CHD™ and PrecisionCHD™, ongoing and planned studies, reimbursement progress, and strategic growth initiatives. Webcast and

PRE 14A - Cardio Diagnostics Holdings, Inc. (0001870144) (Filer)

4 - Cardio Diagnostics Holdings, Inc. (0001870144) (Issuer)

4 - Cardio Diagnostics Holdings, Inc. (0001870144) (Issuer)

4 - Cardio Diagnostics Holdings, Inc. (0001870144) (Issuer)

4 - Cardio Diagnostics Holdings, Inc. (0001870144) (Issuer)

Cardio Diagnostics Holdings, Inc. (NASDAQ:CDIO), an AI-powered precision cardiovascular medicine company, announced that Atlas Healthcare Physicians (AHP), a community-driven, independent physician association (IPA) based in Southern California, will cover Cardio Diagnostics’ tests, Epi+Gen CHD™ and PrecisionCHD™, for their members with prior authorization beginning May 2026. AHP consists of an expansive network of primary care and specialists, hospitals, and ancillary providers serving managed care populations across Los Angeles and Orange County. Providers will recommend Epi+Gen CHD™ or PrecisionCHD™ based on a patient’s medical history. Epi+Gen CHD™ assesses the three-year risk of a co

These evidence-based solutions help employers, brokers, and unions tackle cardiovascular disease, a leading driver of medical claims and lost productivity. Cardio Diagnostics Holdings, Inc. (NASDAQ:CDIO), an AI-powered precision cardiovascular medicine company, today announced that the company will exhibit at four upcoming national benefits conferences, connecting with employers, brokers, union trustees, and plan administrators on a shared challenge: cardiovascular disease (CVD). CVD remains a leading medical claims cost driver for most health plans and a major contributor to absenteeism, disability, and lost workforce productivity. Cardio Diagnostics' clinically validated blood tests,

AUSTIN, Texas, May 20, 2026 (GLOBE NEWSWIRE) -- via IBN – IBN, a multifaceted communications organization engaged in connecting public companies to the investment community, is pleased to announce the release of the latest episode of The BioMedWire Podcast as part of its sustained effort to provide specialized content distribution via widespread syndication channels. The BioMedWire Podcast delivers dynamic interviews with industry experts at the forefront of pharmaceutical and biotech advancement. The latest episode features Dr. Meesha Dogan, CEO and Co-Founder of Cardio Diagnostics Holdings Inc. (NASDAQ:CDIO), a precision cardiovascular medicine company leveraging epigenetics, genetics,

10-Q - Cardio Diagnostics Holdings, Inc. (0001870144) (Filer)

AUSTIN, Texas, April 08, 2026 (GLOBE NEWSWIRE) -- via IBN -- Cardio Diagnostics Holdings Inc. (NASDAQ:CDIO), a precision cardiovascular medicine company leveraging epigenetics, genetics, and artificial intelligence for the prevention and detection of cardiovascular disease, has engaged IBN, a multifaceted financial news and publishing company serving private and public entities, to assist with its corporate communications strategy. Cardio Diagnostics develops and commercializes blood-based clinical tests and data solutions designed to support the prevention, detection, and management of cardiovascular disease. Its approach integrates epigenetic and genetic biomarkers with artificial intel

4 - Cardio Diagnostics Holdings, Inc. (0001870144) (Issuer)

4 - Cardio Diagnostics Holdings, Inc. (0001870144) (Issuer)

4 - Cardio Diagnostics Holdings, Inc. (0001870144) (Issuer)

4 - Cardio Diagnostics Holdings, Inc. (0001870144) (Issuer)

10-K - Cardio Diagnostics Holdings, Inc. (0001870144) (Filer)

8-K - Cardio Diagnostics Holdings, Inc. (0001870144) (Filer)

Cardio Diagnostics Holdings, Inc. (NASDAQ:CDIO) ("Cardio Diagnostics" or the "Company"), a precision cardiovascular medicine company leveraging epigenetics, genetics, and artificial intelligence for the prevention and detection of cardiovascular disease, today announced that it will host an investor conference call on Wednesday, February 18, 2026, at 3 p.m. Central Time. The call will provide an overview of the Company's precision molecular approach to cardiovascular disease prevention and early detection, including updates on its commercially available tests, Epi+Gen CHD™ and PrecisionCHD™, recent breakthrough clinical data, reimbursement progress, and strategic growth initiatives. Web